CAMBRIDGE, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.

“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”

The following posters have been scheduled for presentation:

Number	Poster Title	Presenter	Time
#283	Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break model	Reynald Lescarbeau, Ph.D. Computational Scientist, Bioinformatics	October 19, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET
#280	Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components	David Morrissey, Ph.D. Chief Technology Officer	October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET
#320	DNA repair events after cleavage by CRISPR/Cas9 are not random	Walter Strapps, Ph.D. Senior Director, Biology	October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET
#310	Translating CRISPR/Cas9 genome editing into therapeutics	Tom Barnes, Ph.D. Chief Scientific Officer	October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com

Investor Contacts:

John Graziano
Trout Group
+1 646-378-2942
jgraziano@troutgroup.com

Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.